AUTHOR=Ye Qian-Yun , Lin Qing , Hu Xue-Ling , Yang Yu-Mei , Zheng Bao-Lin , Li Ting , Zhong Wen-Qiang , Wang Hao-Yu , Zhang Zhi-Fen , Luo Bing-Jie , Xiao Ya-Wen , Wu Ai-Ling , Li Yan , Zou Zhuo-Ling , Li Ling-Yu , Li Xiao-Yun , Wang Pan-Pan , Yang Li , Zhu Xiao-Feng , Han Li , Zhang Rong-Hua 

TITLE=Efficacy and safety of combined Chinese and Western medicine in the treatment of knee osteoarthritis: a prospective, multicenter cohort study

JOURNAL=Frontiers in Pharmacology

VOLUME=14

YEAR=2023

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1176980

DOI=10.3389/fphar.2023.1176980

ISSN=1663-9812

ABSTRACT=<p><bold>Purpose:</bold> To conduct a real-world evaluation of the efficacy and safety of combined Chinese and Western medicine in treating knee osteoarthritis (KOA).</p><p><bold>Methods:</bold> A multicenter, prospective cohort study design was employed, enrolling 450 KOA patients (Kellgren-Lawrence score of 3 or less). The patients were divided into a Western medicine treatment group (WM group) and a combined Western and traditional Chinese medicine treatment group (WM-CM group). A 6-week treatment plan was administered, and follow-up visits occurred at 2 weeks, 4 weeks, and 6 weeks after initiating treatment. The primary outcome indicator was the total Western Ontario and McMaster Universities Arthritis Index (WOMAC) score after 6 weeks of treatment. Secondary outcome indicators included WOMAC subscales for pain, stiffness, and joint function, visual analogue scale (VAS) score, physical component summary (PCS), mental component summary (MCS), and clinical effectiveness. The incidence of drug-related adverse events was used as a safety evaluation indicator.</p><p><bold>Results:</bold> A total of 419 patients were included in the final analysis: 98 in the WM group and 321 in the WM-CM group. The baseline characteristics of the two groups were comparable, except for the incidence of stiffness symptoms and stiffness scores. After 6 weeks of treatment, the WM-CM group exhibited superior results to the WM group in improving the total WOMAC score (24.71 ± 1.38 vs. 16.36 ± 0.62, <italic>p</italic> &lt; 0.001). The WM-CM group also outperformed the WM group in WOMAC pain and joint function scores, VAS score, PCS score, MCS score, and clinical effectiveness (<italic>p</italic> &lt; 0.05), which was consistent with the findings of the main evaluation index. Subgroup analysis indicated that the combined Chinese and Western medicine treatment showed more pronounced benefits in patients under 65 years of age and in those with a Kellgren-Lawrence (K-L) classification of 0-I. Throughout the study, no adverse effects were observed in either group.</p><p><bold>Conclusion:</bold> The combination of Chinese and Western medicine demonstrated superiority over Western medicine alone in relieving knee pain symptoms, improving knee function, and enhancing the quality of life for KOA patients with a K-L score of 3 or less. Moreover, the treatment exhibited a good safety profile.</p><p><bold>Clinical Trial Registration:</bold> (<ext-link ext-link-type="uri" xlink:href="https://www.chictr.org.cn/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.chictr.org.cn/</ext-link>), identifier (ChiCTR1900027175).</p>